Your browser doesn't support javascript.
loading
Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption.
Yoshitomo, Aoi; Asano, Satoshi; Hozuki, Shizuka; Tamemoto, Yuta; Shibata, Yukihiro; Hashimoto, Natsumi; Takahashi, Keita; Sasaki, Yoko; Ozawa, Naoka; Kageyama, Michiharu; Iijima, Takeshi; Kazuki, Yasuhiro; Sato, Hiromi; Hisaka, Akihiro.
Afiliación
  • Yoshitomo A; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Asano S; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Hozuki S; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Tamemoto Y; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Shibata Y; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Hashimoto N; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Takahashi K; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Sasaki Y; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Ozawa N; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Kageyama M; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Iijima T; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Kazuki Y; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Sato H; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
  • Hisaka A; Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (A.Y., S.A., S.H., Y.T., N.H., K.T., H.S., A.H.); Toxicology & DMPK Research Department, Teijin Pharma Limited, Tokyo, Japan (S.A., Y.Sa., N.O., M.K., T.I.); Department of Regula
Drug Metab Dispos ; 51(3): 318-328, 2023 03.
Article en En | MEDLINE | ID: mdl-36810197
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinidina / Citocromo P-450 CYP3A Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinidina / Citocromo P-450 CYP3A Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article